(New York, USA) DelveInsight’s “Hepatocellular Carcinoma Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Hepatocellular Carcinoma, historical and forecasted epidemiology as well as the Hepatocellular Carcinoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Hepatocellular Carcinoma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Hepatocellular Carcinoma Market Forecast
Some of the key facts of the Hepatocellular Carcinoma Market Report:
- The Hepatocellular Carcinoma market size is expected to grow at a decent CAGR by 2032.
- According to Surveillance, Epidemiology, and End Results (SEER), in the US, the incidence rate of Hepatocellular Carcinoma and Intrahepatic bile duct cancer was 9.0 per 100,000 which is estimated to be around 42,230 new diagnosed cases in 2021 and the mortality rate was 6.6 per 100,000 per year and the 5-year survival rate was 20.3%. Of them, the stage wise incident cases of Hepatocellular Carcinoma and intrahepatic bile duct cancer was Localized (45%), Regional (26%), Distant (18%), and Unknown (11%).
- Leading Hepatocellular Carcinoma Companies working in the market are AbbVie, H3 Biomedicine Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, Takeda Pharmaceutical Co. Ltd., Johnson & Johnson, Exelixis, Merck & Co., Inc., Pfizer Inc., GlaxoSmithKline, Celgene Corporation, Teva Pharmaceutical Industries Ltd., Amgen, Exelixis, Inc., Genoscience Pharma, Kymab Ltd., Cabozantinib, Eisai Co., Ltd., AVEO Pharmaceuticals, Inc., PharmaBio Development Inc., Ionis Pharmaceuticals, Inc., Merck & Co., Inc., AstraZeneca, Eli Lilly and Company, SillaJen, Inc., Janssen Global Services, LLC, CELGENE CORPORATION, F. Hoffmann-La Roche Ltd, Gilead Sciences, Inc., Transgene, Takeda Pharma, Polaris Pharmaceuticals, Hepion Pharmaceuticals, PROVECTUS BIOPHARMACEUTICALS, INC., Otsuka Pharmaceutical Co., Ltd., Tiziana Life Sciences LTD, and others
- Promising Hepatocellular Carcinoma Therapies for the treatment of HCC include H3B-6527, GNS561, KY1044, Exelixis, lenvatinib, Tivozanib, Durvalumab, Sorafenib, AZD9150, Nivolumab, Tivantinib, GC33(RO5137382), ABT-869, Pembrolizumab, Regorafenib, OPB-31121, Milciclib maleate, amd others
- The Hepatocellular Carcinoma market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Hepatocellular Carcinoma pipeline products will significantly revolutionize the Hepatocellular Carcinoma market dynamics.
Hepatocellular Carcinoma Overview
Hepatocellular Carcinoma defined as a liver tumor not eligible for local therapies given the extent of disease or liver tumors that recurred after local therapies. Patients with HCC usually have significant underlyingliver disease which is associated with poor tolerability to systemic chemotherapy.
Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer, accounting for approximately 75-85% of all liver cancer cases. It originates from hepatocytes, the main cell type in the liver. HCC is often associated with underlying liver diseases, such as chronic hepatitis B or C infection, cirrhosis (scarring of the liver), or non-alcoholic fatty liver disease (NAFLD).
Get a Free sample for the Hepatocellular Carcinoma Market Report - https://www.delveinsight.com/sample-request/hepatocellular-carcinoma-market
Hepatocellular Carcinoma Epidemiology
The Hepatocellular Carcinoma epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Hepatocellular Carcinoma Epidemiology Segmentation:
The Hepatocellular Carcinoma market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Total Prevalence of Hepatocellular Carcinoma
- Prevalent Cases of Hepatocellular Carcinoma by severity
- Gender-specific Prevalence of Hepatocellular Carcinoma
- Diagnosed Cases of Episodic and Chronic Hepatocellular Carcinoma
Download the report to understand which factors are driving Hepatocellular Carcinoma epidemiology trends- https://www.delveinsight.com/sample-request/hepatocellular-carcinoma-market
Hepatocellular Carcinoma Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hepatocellular Carcinoma market or expected to get launched during the study period. The analysis covers Hepatocellular Carcinoma market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Hepatocellular Carcinoma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Hepatocellular Carcinoma Therapies and Key Companies
- H3B-6527: H3 Biomedicine Inc.
- GNS561: Genoscience Pharma
- KY1044: Kymab Limited
- Exelixis: Cabozantinib
- lenvatinib: Eisai Co., Ltd.
- Tivozanib: AVEO Pharmaceuticals, Inc.
- Durvalumab: AstraZeneca
- Sorafenib: PharmaBio Development Inc.
- AZD9150: Ionis Pharmaceuticals, Inc.
- Nivolumab: Bristol-Myers Squibb
- Tivantinib: Daiichi Sankyo, Inc.
- GC33(RO5137382): Chugai Pharmaceutical
- ABT-869: AbbVie
- Pembrolizumab: Bayer
- Regorafenib: Merck Sharp & Dohme LLC
- OPB-31121: Otsuka Pharmaceutical Co., Ltd.
- Milciclib maleate: Tiziana Life Sciences LTD
Discover more about therapies set to grab major Hepatocellular Carcinoma market share - https://www.delveinsight.com/sample-request/hepatocellular-carcinoma-market
Hepatocellular Carcinoma Market Strengths
Increasing Incidence due to the change in lifestyle, increasing obesity, presence of a strong pipeline is expected to bring a positive change in the market.
Scope of the Hepatocellular Carcinoma Market Report
- Study Period: 2019–2032
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key Hepatocellular Carcinoma Companies: AbbVie, H3 Biomedicine Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, Takeda Pharmaceutical Co. Ltd., Johnson & Johnson, Exelixis, Merck & Co., Inc., Pfizer Inc., GlaxoSmith Kline, Celgene Corporation, Teva Pharmaceutical Industries Ltd., Amgen, Exelixis, Inc., Genoscience Pharma, Kymab Ltd., Cabozantinib, Eisai Co., Ltd., AVEO Pharmaceuticals, Inc., PharmaBio Development Inc., Ionis Pharmaceuticals, Inc., Merck & Co., Inc., AstraZeneca, Eli Lilly and Company, SillaJen, Inc., Janssen Global Services, LLC, CELGENE CORPORATION, F. Hoffmann-La Roche Ltd, Gilead Sciences, Inc., Transgene, Takeda Pharma, Polaris Pharmaceuticals, Hepion Pharmaceuticals, PROVECTUS BIOPHARMACEUTICALS, INC., Otsuka Pharmaceutical Co., Ltd., Tiziana Life Sciences LTD, and others
- Hepatocellular Carcinoma Drugs: H3B-6527, GNS561, KY1044, Exelixis, lenvatinib, Tivozanib, Durvalumab, Sorafenib, AZD9150, Nivolumab, Tivantinib, GC33(RO5137382), ABT-869, Pembrolizumab, Regorafenib, OPB-31121, Milciclib maleate, and others
- Hepatocellular Carcinoma Therapeutic Assessment: Hepatocellular Carcinoma current marketed and Hepatocellular Carcinoma emerging therapies
- Hepatocellular Carcinoma Market Dynamics: Hepatocellular Carcinoma market drivers and Hepatocellular Carcinoma market barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, Hepatocellular Carcinoma Unmet Needs, KOL’s views, Analyst’s views, Hepatocellular Carcinoma Market Access and Reimbursement
To know more about Hepatocellular Carcinoma companies working in the treatment market, visit- https://www.delveinsight.com/sample-request/hepatocellular-carcinoma-market
Table of Contents
1. Hepatocellular Carcinoma Market Report Introduction
2. Executive Summary for Hepatocellular Carcinoma
3. SWOT analysis of Hepatocellular Carcinoma
4. Hepatocellular Carcinoma Patient Share (%) Overview at a Glance
5. Hepatocellular Carcinoma Market Overview at a Glance
6. Hepatocellular Carcinoma Disease Background and Overview
7. Hepatocellular Carcinoma Epidemiology and Patient Population
8. Country-Specific Patient Population of Hepatocellular Carcinoma
9. Hepatocellular Carcinoma Current Treatment and Medical Practices
10. Hepatocellular Carcinoma Unmet Needs
11. Hepatocellular Carcinoma Emerging Therapies
12. Hepatocellular Carcinoma Market Outlook
13. Country-Wise Hepatocellular Carcinoma Market Analysis (2019–2032)
14. Hepatocellular Carcinoma Market Access and Reimbursement of Therapies
15. Hepatocellular Carcinoma Market Drivers
16. Hepatocellular Carcinoma Market Barriers
17. Hepatocellular Carcinoma Appendix
18. Hepatocellular Carcinoma Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting
